文献速递肿瘤 PET/CT

18F FDG PET/MRI联合肝细胞特异性对比剂用于直肠癌M分期的初步经济学评价

18F FDG PET/MRI with hepatocyte-specific contrast agent for M staging of rectal cancer: a primary economic evaluation.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2021-03-09

该研究基于马尔可夫模拟构建决策模型,比较全身18F FDG PET/MRI(联合肝细胞特异性对比剂)与标准影像(盆腔MRI+胸腹盆CT)用于直肠癌初始分期经济性。结果显示PET/MRI总成本52,186美元、标准影像51,672美元,增量成本效果比为每QALY 70,291美元,低于100,000美元/QALY的支付意愿阈值。

要点

  • 全身18F FDG PET/MRI用于直肠癌初始分期的ICER为每QALY 70,291美元。
  • 支付意愿阈值设为100,000美元/QALY,PET/MRI在经济性上可接受。
  • 结果对输入参数变化具有较高稳健性。

核心结论

  • 从成本效果角度看,全身18F FDG PET/MRI可作为直肠癌初始分期的可行诊断策略。

研究设计与样本

  • 研究构建了包含全身18F FDG PET/MRI(联合肝细胞特异性对比剂)与盆腔MRI+胸腹盆CT的决策模型,基于马尔可夫模拟估算QALYs与终生成本。
  • 模型输入参数来自近期文献综述,支付意愿阈值设定为100,000美元/QALY。
  • 研究对诊断参数与成本进行了确定性敏感性分析,并使用蒙特卡洛建模进行概率敏感性分析。

主要发现

  • 基础病例场景下,全身18F FDG PET/MRI策略总成本为52,186美元,标准影像总成本为51,672美元。
  • 全身18F FDG PET/MRI的期望效果为3.542 QALYs,标准影像为3.535 QALYs。
  • 由此计算得到PET/MRI的增量成本效果比为每QALY 70,291美元。
  • 结果对输入参数变化具有较高稳健性。

关键数值与推荐

  • 支付意愿阈值设为100,000美元/QALY。
  • PET/MRI增量成本效果比为每QALY 70,291美元,低于上述阈值。

临床怎么用

  • 对于直肠癌初始分期,在支付意愿阈值为100,000美元/QALY的前提下,可考虑将全身18F FDG PET/MRI作为标准影像的替代诊断策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Rectal cancer is one of the most frequent causes of cancer-related morbidity and mortality in the world. Correct identification of the TNM state in primary staging of rectal cancer has critical implications on patient management. Initial evaluations revealed a high sensitivity and specificity for whole-body PET/MRI in the detection of metastases allowing for metastasis-directed therapy regimens. Nevertheless, its cost-effectiveness compared with that of standard-of-care imaging (SCI) using pelvic MRI + chest and abdominopelvic CT is yet to be investigated. Therefore, the aim of this study was to analyze the cost-effectiveness of whole-body 18F FDG PET/MRI as an alternative imaging method to standard diagnostic workup for initial staging of rectal cancer. METHODS: For estimation of quality-adjusted life years (QALYs) and lifetime costs of diagnostic modalities, a decision model including whole-body 18F FDG PET/MRI with a hepatocyte-specific contrast agent and pelvic MRI + chest and abdominopelvic CT was created based on Markov simulations. For obtaining model input parameters, review of recent literature was performed. Willingness to pay (WTP) was set to $100,000/QALY. Deterministic sensitivity analysis of diagnostic parameters and costs was applied, and probabilistic sensitivity was determined using Monte Carlo modeling. RESULTS: In the base-case scenario, the strategy whole-body 18F FDG PET/MRI resulted in total costs of $52,186 whereas total costs of SCI were at $51,672. Whole-body 18F FDG PET/MRI resulted in an expected effectiveness of 3.542 QALYs versus 3.535 QALYs for SCI. This resulted in an incremental cost-effectiveness ratio of $70,291 per QALY for PET/MRI. Thus, from an economic point of view, whole-body 18F FDG PET/MRI was identified as an adequate diagnostic alternative to SCI with high robustness of results to variation of input parameters. CONCLUSION: Based on the results of the analysis, use of whole-body 18F FDG PET/MRI was identified as a feasible diagnostic strategy for initial staging of rectal cancer from a cost-effectiveness perspective.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Gassert FG, Rübenthaler J, Cyran CC, et al. 18F FDG PET/MRI with hepatocyte-specific contrast agent for M staging of rectal cancer: a primary economic evaluation. Eur J Nucl Med Mol Imaging. 2021. PMID: 33686457. doi:10.1007/s00259-021-05193-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。